Department of Vermont Health Access
Pharmacy Benefits Management Program

*DUR Board Meeting Agenda*

January 15, 2013  6:00 – 8:30 p.m.

1. **Executive Session**  6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes**  6:30 - 6:35
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates**  6:35 - 6:45
   - Updates

4. **Medical Director Update**  6:45 - 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings**  6:45 - 7:00
   - Antipsychotic Medications in Children - Survey
   - Practice Change Strategies
   - Displaying Prior Authorization End Dates to Pharmacies

6. **RetroDUR/DUR**  7:00 – 7:30
   - Narcotic Analgesics – continued use of short acting with no long acting
   - Skeletal Muscle Relaxants

7. **Clinical Update: Drug Reviews**  7:30 – 7:45
   (Public comment prior to Board action)

   **Abbreviated New Drug Reviews**
   - Binosto® (alendronate sodium) effervescent tablet
   - Rayos® (prednisone) delayed release tablet

   **Full New Drug Reviews**
   - Elelyso® (taliglucerase alfa) vial for injection
8. Therapeutic Drug Classes – Periodic Review  7:45 – 8:15
(Public comment prior to Board action)
Class review documents available on DVHA web site 01/15/2013 @ 12 Noon
   - Antidepressants: SNRI and Miscellaneous
   - Gastrointestinal: Proton Pump Inhibitors
   - Ophthalmic Immunomodulators (Restasis®)
   - Pancreatic Enzymes (including new drug reviews of Pertzye®, Ultresa® and Viokace®)

9. New Managed Therapeutic Drug Classes  8:15 – 8:20
(Public comment prior to Board action)
   - Gastrointestinal: Anti-ulcer: H.Pylori Combination Therapy

10. Review of Newly-Developed/Revised  8:20 – 8:20
    Clinical Coverage Criteria and/or Preferred Products
(Public comment prior to Board action)
   - None

11. General Announcements  8:20– 8:30
    Selected FDA Safety Alerts
    - Chantix (varenicline): Safety review update of the risk of cardiovascular adverse events
    - Incivek (telaprevir): Serious skin reactions after used in combination treatment with the Hepatitis C drugs peginterferon alfa, and ribavirin
    - Pradaxa (dabigatran etexilate mesylate): Not be used in patients with mechanical prosthetic heart valves
    - Xyrem (sodium oxybate): Warning against use with alcohol or drugs causing respiratory depression

12. Adjourn  8:30